NCT07169383View on ClinicalTrials.gov

Oral Melatonin Versus Oral Tranexamic Acid in the Management of Melasma

PHASE2Enrolling by invitationINTERVENTIONAL
Enrollment

160

Participants

Timeline

Start Date

June 28, 2025

Primary Completion Date

December 28, 2025

Study Completion Date

December 28, 2025

Conditions
Melasma (Facial Melasma)
Interventions
DRUG

Melatonin tablet

Group A will receive oral melatonin 5mg every night for 3 months

DRUG

Tranexamic Acid (TXA)

Group B will receive oral tranexamic acid 250mg twice daily for 3 months.

Trial Locations (1)

44000

PAEC General Hospital Islamabad Pakistan, Islamabad

All Listed Sponsors
lead

Hina Malik

OTHER